Skip to Content

Press Releases

Press Releases

Nov 13 2019
Intec Pharma to Participate in Jefferies London Healthcare Conference
JERUSALEM , Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference .  Jefferies London Healthcare Conference Date: November 20-21, 2019 Company
Nov 12 2019
Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update
JERUSALEM , Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2019 . Highlights of the third quarter 2019 and recent weeks include: Presented two posters highlighting data
Sep 25 2019
Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society
  JERUSALEM , Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill ® Carbidopa/Levodopa (AP-CD/LD), were presented yesterday at
Sep 16 2019
Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society
JERUSALEM , Sept. 16, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the
Sep 03 2019
Intec Pharma to Participate in September Investment Conferences
JERUSALEM , Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September. HC Wainwright 21 st Annual Global Investment Conference Date: September
Aug 09 2019
Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update
JERUSALEM , Aug. 9, 2019 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and six months ended June 30 , 2019.   Highlights of the second quarter 2019 and recent weeks include: Completed the qualification studies for the
Jul 22 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Conference Call to begin at 8:30 am ET JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill ®
Jul 01 2019
Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery
Peer-reviewed journal article highlights unique oral delivery platform's ability to enhance pharmacokinetic and therapeutic benefit for challenging drugs JERUSALEM , July 1, 2019 /PRNewswire/ --   Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that a review
Jun 25 2019
Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders
Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announces that results from an earlier Phase 2 clinical
Jun 19 2019
Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders
JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) were highlighted yesterday in a
Displaying 1 - 10 of 98